ArticleJournal of thoracic disease2012

Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study.

Millie Das et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.